interview (≥55 vs <55 years); (2) residence (urban/nonurban); (3) ET plan (yes/no); current symptoms, including (4) fatigue, (5) hot flashes, and (6) vaginal dryness (yes/no); (7) time since diagnosis (months); and (8) discharge status (cancer center
Search Results
Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis
Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis
-related complications, including second malignant neoplasms (SMNs), cardiovascular disease (CVD), ototoxicity, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, infertility, anxiety, depression, cognitive impairment, and chronic cancer-related fatigue
Lois Ramondetta
Odors 24 Fatigue 25 , 26 Pain 27 , 28 Constipation 27 Unfortunately, patients with cervical cancer, because of its association with low socioeconomic status, are often without the extensive social and clinical supportive services that are
Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess
fatigue (n=22), nausea (n=14), anorexia (n=9), and thrombocytopenia (n=7) ( Table 3 ). Grade 3 toxicities were fatigue (n=3), thrombocytopenia (n=1), neutropenia (n=3), hypertension (n=1), and decreased white blood cell count (n=1). Two patients
Gabrielle B. Rocque, Richard A. Taylor, Aras Acemgil, Xuelin Li, Maria Pisu, Kelly Kenzik, Bradford E. Jackson, Karina I. Halilova, Wendy Demark-Wahnefried, Karen Meneses, Yufeng Li, Michelle Y. Martin, Carol Chambless, Nedra Lisovicz, Mona Fouad, Edward E. Partridge, Elizabeth A. Kvale, and the Patient Care Connect Group
distress at initial assessment were pain (408 of 5,254 cases reporting a cause of distress), balance/mobility difficulties (404 cases), and fatigue (399 cases; Figure 2A ). This breakdown was similar for formal and informal DTs. Patients with distress
Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson
). Of 1,685 patients who received PARPi, incidence of any AE, regardless of grade, was 98.5% (95% CI, 97.2–99.2%). Common AEs were: nausea (incidence rate, 68.9% and 95% CI, 58.7%–77.5%), fatigue (56.3%, 45.3%–66.8%), anemia (46.3%, 37
Meagan S. Whisenant, Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams
. Fatigue and distress were described by most women regardless of treatment, whereas arm swelling was reported only by women who had undergone surgery, and skin changes were reported primarily by women who received radiation therapy. Patients volunteered
Olivia G. Fahey, Elizabeth N. Dow, Jennifer K. Piccolo, and Ticiana A. Leal
pharmacists were gastrointestinal (n=15) and dermatologic (n=6). Endocrine (n=7) and dermatologic (n=7) were the most common grade 1 or 2 irAEs identified by other providers. There were 4 grade 3 irAEs (endocrine, fatigue, liver, and pneumonitis) identified by
Irbaz Bin Riaz, Saad Ullah Malik, Muhammad Husnain, Qurat Ul Ain Riaz Sipra, Warda Faridi, Farva R. Gondal, Thanh Ho, Siddhartha Yadav, Zhen Wang, and Manish Kohli
.90; 95% CI, 0.67–1.19). Use of TKIs was associated with significantly increased risk of drug toxicity. Increased risk of grade 3 or 4 adverse events (RR=5.110; 95% CI, 3.765–6.935), diarrhea (RR=10.725; 95% CI, 4.672–24.622), fatigue (RR=3.310; 95% CI, 1
Jorge Cortes, Clara Chen, Michael Mauro, Neela Kumar, Catherine Davis, and Stuart L. Goldberg
baseline fatigue (OR=1.799; P =0.072). Conclusions: Most pts treated with 1L NIL were started on 300 or 400 mg (BID); however, 1 in 4 pts required a dose reduction, most often due to intolerance. Physicians at academic centers were more likely to reduce
